Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.
Trientine Hydrochloride Capsules USP (RLD: Syprine) had an annual sales of approximately USD 86 million in the U.S.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content